Manns M, Maasoumy B
Nat Rev Gastroenterol Hepatol. 2022; 19(8):533-550.
PMID: 35595834
PMC: 9122245.
DOI: 10.1038/s41575-022-00608-8.
Cheema S, Rehman M, Hussain G, Cheema S, Gilani N
BMC Nephrol. 2019; 20(1):438.
PMID: 31779583
PMC: 6883698.
DOI: 10.1186/s12882-019-1631-4.
Marsella M, Ricchi P
J Blood Med. 2019; 10:323-334.
PMID: 31572038
PMC: 6756274.
DOI: 10.2147/JBM.S186362.
Lohmann V
Med Microbiol Immunol. 2018; 208(1):3-24.
PMID: 30298360
DOI: 10.1007/s00430-018-0566-x.
Kelly L, Badhan A, Roberts G, Mbisa J, Harris M
J Gen Virol. 2017; 98(10):2495-2506.
PMID: 28984238
PMC: 5725995.
DOI: 10.1099/jgv.0.000932.
Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
Xue Y, Zhang L, Wang L, Li T, Qu Y, Liu F
World J Gastroenterol. 2017; 23(32):5969-5976.
PMID: 28932089
PMC: 5583582.
DOI: 10.3748/wjg.v23.i32.5969.
Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
Yu J, Lee J, Lee K, Kim J
Virol J. 2017; 14(1):164.
PMID: 28836992
PMC: 5571669.
DOI: 10.1186/s12985-017-0826-1.
Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.
Geddawy A, Ibrahim Y, Elbahie N, Ibrahim M
J Transl Int Med. 2017; 5(1):8-17.
PMID: 28680834
PMC: 5490957.
DOI: 10.1515/jtim-2017-0007.
Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90.
Braga A, Carneiro B, Nogueira Batista M, Akinaga M, Rahal P
Cell Stress Chaperones. 2016; 22(1):113-122.
PMID: 27858224
PMC: 5225065.
DOI: 10.1007/s12192-016-0747-8.
Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.
Keshvari M, Alavian S, Behnava B, Pouryasin A, Craig J, Sharafi H
J Clin Lab Anal. 2016; 31(4).
PMID: 27735085
PMC: 6816931.
DOI: 10.1002/jcla.22063.
Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands.
Van Santen D, de Vos A, Matser A, Willemse S, Lindenburg K, Kretzschmar M
PLoS One. 2016; 11(10):e0163488.
PMID: 27711200
PMC: 5053429.
DOI: 10.1371/journal.pone.0163488.
Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report.
Seifert L, Heinzow H, Kabar I, Christensen S, Husing A, Schmidt H
Am J Case Rep. 2016; 17:605-10.
PMID: 27554644
PMC: 4999016.
DOI: 10.12659/ajcr.895839.
Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan.
Sagan S, Dupont B, Grebely J, Krajden M, MacParland S, Raven J
Can J Gastroenterol Hepatol. 2016; 2016:5743521.
PMID: 27446849
PMC: 4904693.
DOI: 10.1155/2016/5743521.
Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.
Lawitz E, Dvory-Sobol H, Doehle B, Worth A, McNally J, Brainard D
Antimicrob Agents Chemother. 2016; 60(9):5368-78.
PMID: 27353271
PMC: 4997818.
DOI: 10.1128/AAC.00763-16.
Advances in hepatitis C therapy: What is the current state - what come's next?.
Zopf S, Kremer A, Neurath M, Siebler J
World J Hepatol. 2016; 8(3):139-47.
PMID: 26839638
PMC: 4724577.
DOI: 10.4254/wjh.v8.i3.139.
Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon.
Belga S, Doucette K
World J Gastroenterol. 2016; 22(4):1650-63.
PMID: 26819530
PMC: 4721996.
DOI: 10.3748/wjg.v22.i4.1650.
The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses.
Pecheur E, Borisevich V, Halfmann P, Morrey J, Smee D, Prichard M
J Virol. 2016; 90(6):3086-92.
PMID: 26739045
PMC: 4810626.
DOI: 10.1128/JVI.02077-15.
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
Yang S, Kao J
Hepatol Int. 2015; 10(2):258-66.
PMID: 26542068
DOI: 10.1007/s12072-015-9668-3.
Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance.
Roche B, Coilly A, Roque-Afonso A, Samuel D
Viruses. 2015; 7(9):5155-68.
PMID: 26404355
PMC: 4584308.
DOI: 10.3390/v7092864.
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.
Janczewska E, Flisiak R, Zarebska-Michaluk D, Kozielewicz D, Berak H, Dobracka B
Medicine (Baltimore). 2015; 94(38):e1411.
PMID: 26402801
PMC: 4635741.
DOI: 10.1097/MD.0000000000001411.
